| Literature DB >> 30170791 |
Chiara Fenoglio1, Emanuela Oldoni2, Maria Serpente3, Milena A De Riz4, Marina Arcaro5, Marianna D'Anca6, Anna M Pietroboni7, Alberto Calvi8, Elisabetta Lecchi9, An Goris10, Klara Mallants11, Bénédicte Dubois12, Cristoforo Comi13, Roberto Cantello14, Elio Scarpini15, Daniela Galimberti16.
Abstract
LncRNA PCR arrays containing 90 common LncRNAs were used to screen lncRNA expression levels in PBMC from a discovery population of patients with MS. Data from discovery and replications cohorts showed a generalized dysregulation of lncRNA levels in MS patients compared with controls. MALAT1, MEG9, NRON, ANRIL, TUG1, XIST, SOX2OT, GOMAFU, HULC, BACE-1AS were significantly downregulated in MS patients in comparison with controls. Therefore, we performed a validation analysis in an independent cohort of Belgian origin. In this study, NRON and TUG1 downregulations in MS patients compared with controls were confirmed (p ≤ .05 and p ≤ .0001 respectively), whereas considering the other lncRNAs, the statistical threshold was not reached. LncRNAs profiling could thus represent a new challenge in the research of easy detectable biomarkers of disease susceptibility and progression.Entities:
Keywords: Biomarker; Gene expression; Multiple Sclerosis; Non coding RNA
Mesh：
Substances：
Year: 2018 PMID： 30170791 DOI： 10.1016/j.jneuroim.2018.08.008
Source DB: PubMed Journal: J Neuroimmunol ISSN： 0165-5728 Impact factor: 3.478